Stockreport

Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study [Yahoo! Finance]

Kezar Life Sciences, Inc.  (KZR) 
Last kezar life sciences, inc. earnings: 8/7 04:05 pm Check Earnings Report
PDF PALIZADE Phase 2b trial in patients with active lupus nephritis (LN) and focus clinical development efforts on zetomipzomib in autoimmune hepatitis (AIH) Last week, th [Read more]